Bietti's Crystalline Dystrophy is a rare genetic disorder affecting the eyes, characterized by the accumulation of small, yellow-white crystals in the retina and the degeneration of the choroid. Typically diagnosed in early adulthood, it initially manifests as night blindness and gradually progresses to peripheral vision loss. The condition is caused by mutations in the CYP4V2 gene, which disrupts lipid metabolism in the retina. Diagnosis involves detailed ophthalmic examinations such as fundus photography and optical coherence tomography (OCT) to detect the characteristic retinal changes and crystals.
Currently, treatment options are limited, focusing on managing symptoms and slowing disease progression through regular monitoring and lifestyle adjustments. Genetic counseling is essential for affected individuals and their families due to the condition's autosomal recessive inheritance pattern. Ongoing research aims to identify therapeutic strategies targeting lipid metabolism abnormalities to potentially improve outcomes for patients with Bietti's Crystalline Dystrophy.







Title : Why a paediatric orthoptic oncology service matters
Shenika Tailor, University Hospitals of Leicester NHS Trust, United Kingdom
Title : Stereotactic radiotherapy for wet age-related macular degeneration: year 4 results of a randomised, double-masked, sham-controlled trial
Tim Jackson, King’s College London, United Kingdom